Unknown Author
March 4, 2026
GSK to Acquire 35Pharma
1 min
AI-made summary
- • GSK plc is acquiring 35Pharma Inc., a Canadian clinical-stage biopharmaceutical company, for $950 million in an all-cash transaction. • The acquisition includes HS235, an investigational medicine targeting pulmonary hypertension and pulmonary arterial hypertension. • Paul, Weiss is advising GSK on the deal, with a team comprising corporate, intellectual property, antitrust, executive compensation, tax, and litigation specialists.
Paul, Weiss is advising GSK plc in its $950 million all-cash acquisition of 35Pharma Inc., a Canada-based, private, clinical-stage biopharmaceutical company specializing in the development of novel protein-based therapeutics. The deal includes the acquisition of HS235, a potential best-in-class investigational medicine for the treatment of pulmonary hypertension and pulmonary arterial hypertension.
The Paul, Weiss team is led by corporate partners Krishna Veeraraghavan and Benjamin Goodchild; intellectual property partners Jonathan Ashtor, Meggin Bednarczyk and Marisa Geiger, and counsel Matthew Rosenberg; antitrust partner Christopher Wilson; executive compensation partner Jean McLoughlin; tax partner Brian Krause; and litigation counsel Audrey Paquet.
Article Author
Unknown Author
The Sponsor